Cullinan Therapeutics (CGEM) Competitors

Cullinan Therapeutics (NASDAQ:CGEM) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability.

Does the MarketBeat Community prefer CGEM or XNCR?

Xencor received 455 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 80.43% of users gave Cullinan Therapeutics an outperform vote while only 72.89% of users gave Xencor an outperform vote.

Company	Underperform	Outperform
Cullinan Therapeutics	Outperform Votes 37 80.43%	Underperform Votes 9 19.57%
Xencor	Outperform Votes 492 72.89%	Underperform Votes 183 27.11%

Which has stronger earnings & valuation, CGEM or XNCR?

Xencor has higher revenue and earnings than Cullinan Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	$18.94M	68.16	-$153.16M	-$3.13	-7.16
Xencor	$168.34M	7.96	-$126.09M	-$2.19	-9.93

Is CGEM or XNCR more profitable?

Cullinan Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -82.23%. Xencor's return on equity of -20.29% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-28.65%	-27.14%
Xencor	-82.23%	-20.29%	-15.72%

Do insiders and institutionals have more ownership in CGEM or XNCR?

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 5.2% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more volatility and risk, CGEM or XNCR?

Cullinan Therapeutics has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Do analysts recommend CGEM or XNCR?

Cullinan Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 42.86%. Xencor has a consensus price target of $35.43, suggesting a potential upside of 62.96%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xencor	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Does the media prefer CGEM or XNCR?

In the previous week, Cullinan Therapeutics had 7 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Cullinan Therapeutics and 3 mentions for Xencor. Xencor's average media sentiment score of 1.15 beat Cullinan Therapeutics' score of 0.66 indicating that Xencor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cullinan Therapeutics and Xencor tied by winning 9 of the 18 factors compared between the two stocks.